Paveena Yamanont

  • B.Sc (Marine Science) Chulalongkorn University, Thailand
  • M.Sc. (Pharmacology) Chulalongkorn University, Thailand
Current Research
  • Lipid oxidation in thalassemia
  1. Morales NP*, Sirijaroonwong S, Yamanont P, Phisalaphong C. Electron paramagnetic resonance study of free radical scavenging activity of curcumin its demethoxy and hydrogenated derivatives. Biological and Pharmaceutical Bulletin 2015; 38: 1478-1483.
  2. Rodrat S, Yamanont P, Tankanitlert J, Chantraraksri U, Fucharoen S, Morales NP. Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-thalassemia/hemoglobin E patients. Pharmacology. 2012;90(1-2):88-94.
  3. Limenta LM, Jirasomprasert T, Jittangprasert P, Wilairat P, Yamanont P, Chantharaksri U, Fucharoen S, Morales NP. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status. Clin Pharmacokinet. 2011;50(1):41-50.
  4. Morales NP, Yamanont P, Jirasomprasert T, Wilairat P, Chantharaksri U, Chuncharunee S, et al. Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers.Int J Clin Pharmacol Ther. 2009;47(5):358-64.
  5. Jirasomprasert T, Morales NP, Limenta LM, Sirijaroonwong S, Yamanont P, Wilairat P, et al. Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in β-thalassemia. Free Radic Res. 2009;43(5):485-91.
  6. Morales NP, Charlermchoung C, Luechapudiporn R, Yamanont P, Fucharoen S, Chantharaksri U. Lipid fluidity at different regions in LDL and HDL of β-thalassemia/Hb E patients. Biochem Biophys Res Commun. 2006;350(3):698-703.
  7. Sibmooh N, Yamanont P, Krudsood S, Leowattana W, Brittenham G, Looareesuwan S, et al. Increased fluidity and oxidation of malarial lipoproteins: relation with severity and induction of endothelial expression of adhesion molecules. Lipids Health Dis. 2004;3:15.